TECH (Bio-Techne Inc.) יחס יתרת חוב לטווח ארוך להון

New management at Bio-Techne Corporation (TECH) is optimizing costs, anticipating a biotech sector recovery driven by a broad portfolio of solutions. Financial stability is underpinned by consistent demand for laboratory reagents, maintaining free cash flow at 0.14. The stock price trend on the GURU.Markets platform confirms high business margins based on the scalable production of specific proteins and customer lock-in via unique formulas.

The long-term debt-to-equity ratio measures financial leverage, determining the proportion of borrowed funds within the company's asset financing structure. For Bio-Techne Corporation (TECH), with its predictable revenues from consumables sales, low reliance on debt minimizes default risks. By analyzing the long-term debt-to-equity structure, an investor can assess the balance between conservative management and the pace of business expansion.